CO5261503A1 - Derivados de piperazina y piperidina - Google Patents

Derivados de piperazina y piperidina

Info

Publication number
CO5261503A1
CO5261503A1 CO01009891A CO01009891A CO5261503A1 CO 5261503 A1 CO5261503 A1 CO 5261503A1 CO 01009891 A CO01009891 A CO 01009891A CO 01009891 A CO01009891 A CO 01009891A CO 5261503 A1 CO5261503 A1 CO 5261503A1
Authority
CO
Colombia
Prior art keywords
branched
straight
alkenyl
alkyl
ring
Prior art date
Application number
CO01009891A
Other languages
English (en)
Inventor
Ronald Charles Tomlinson
David Lauffer
Michael Mullican
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CO5261503A1 publication Critical patent/CO5261503A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Un compuesto de la fórmula:<EMI FILE="01009891_1" ID="1" IMF=JPEG >en donde:cada Q es un sistema de anillo monocíclico, bicíclico o tricíclico, en donde en dicho sistema de anillo:cada anillo es independientemente insaturado de manera parcial o completamente saturado;cada anillo comprende 3 a 7 átomos de anillo independientemente seleccionado de C, N, O o S;no más de cuatro átomos del anillo en Q son seleccionados de N, O o S;cualquier S es opcionalmente reemplazado con S (O) o S(O)2;al menos un anillo comprende un átomo de anillo N que es sustituido con R1;f. De uno a cinco átomos de hidrógeno en Q son opcional e independientemente reemplazados con halo-OH, =O, =N-OR1, alquilo recto o ramificado (C1-C6), alquilo Ar- sustituido-(C1-C6)-recto o ramificado, alquenilo o alquinilo recto o ramificado (C2-C6), alquenilo o alquinilo Ar-sustituido-g. (C2C6)-recto o ramificado, alquilo O-C1-C6)-recto o ramificado, O-[alquilo (C1-C6)-recto o ramificado]-Ar, alquenilo o alquinilo O-(C2-C6)-recto o ramificado, O-[alquenilo o alquinilo (C2-C6)-recto o ramificado]-Ar, o O-Ar; y - 2 -h. Q no es un indol o una porción piroglutámica, en dondeCada R1 es independientemente seleccionado de alquilo (C1-C6)-recto o ramificado, alquilo Ar-sustituido-(C1-C6)-recto o ramificado, alquilo cicloalquilo (C1-C6)-recto o ramificado, o alquenilo o alquinilo (C2-C6)-recto o ramificado, o alquenilo alquinilo Ar-sustituido-(C2-C6)-recto o ramificado; en dondeUno a dos grupos CH2 de dichas cadenas de alquilo, alquenilo, o alquinilo, en R1 son opcional e independientemente reemplazadas con O, S, S(O), S(O)2, C(O) o N(R2), en donde cuando R1 está unido al nitrógeno, el grupo CH2 del R1 unido directamente a dicho nitrógeno no puede ser reemplazado con C(O);Ar se selecciona de fenilo, 1-naftilo, 2-naftilo, indenilo, azulenilo, 2-furilo, 3-furilo, 2-tienilo, 3-tienilo, 2-piridilo, 3-piridilo, 4-piridilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, piraxolilo, pirazolinilo, piraolidinilo, isoxazolilo, isotiazolilo, 1,2,3-oxadiazolilo, 1,2,3-triazolilo, 1,3,4-tiadiazolilo, 1,2,4-triazolilo, 1,2,4-oxadiazolilo, 1,2,4-tiadiazolilo, 1,2,3-tiadiazolilo, benoxazolilo, piridazinilo, 2-pirimidinilo, 4- pirimidinilo, 5- pirimidinilo, pirazinilo, 1,3,5-triazinilo, 1,3,5-tritianilo, indolisinilo, indolilo, isoindolilo, 3H-indolilo, indolinilo, benzo[b]furanilo, benzo[b]tiofenilo, 1H-indazolilo, benzimidiazolilo, benztiazolilo, purinilo, 4H-quinolisinilo, quinolinilo, 1,2,3,4-tetrahidroisoquinolinilo, isoquinolinilo, 1,2,3,4-tetrahidroquinolinilo, cinolinilo, eftalasinilo, quinazolinilo, quinoxalinilo, 1,8-naftiridinilo, o cualquier otro sistema de anillo monocíclico o bicíclico químicamente factible, en donde cada anillo consiste de 5 a 7 átomos de anillo en donde cada anillo comprende 0 a 3 héteroátomos independientemente seleccionados de N, O, o S, en dondeCada Ar es opcionalmente e independientemente sustituido con uno a tres sustituyentes seleccionados de halo, hidroxi, nitro, =O, -SO3H, trifluorometilo, trifluorometoxi, alquilo (C1-C6)-recto o ramificado, alquenilo (C1-C6)-recto o ramificado, O-[alquilo (C1-C6)-recto o ramificado], O-[alquenilo (C1-C6)-recto o ramificado], O-benzilo, O-fenilo, 1,2-metilenedioxi, -N(R3)(R4), carboxilo, N-(alquilo (C1-C6)-recto o ramificado o alquenilo (C2-C6)-recto o ramificado) carboxamidas, N,N-di-(alquilo C1-C6-recto o ramificado o alquenilo C2-C6-recto o ramificado) carboxamidas, N-(alquilo C1-C6-recto o ramificado o alquenilo C2-C6-recto o ramificado) sulfonamidas, o N,N-di-(alquilo C1-C6-recto o ramificado o alquenilo C2-C6-recto o ramificado) sulfonamidas;Cada uno de los R3 y R4 son independientemente seleccionados de alquilo (C1-C6)-recto o ramificado, alquenilo o alquinilo (C2-C6)-recto o ramificado, hidrógeno, fenilo o benzilo, o en donde R3 y R4 son tomados juntos con el átomo de nitrógeno al cual ellos están unidos para formar un anillo héterocíclico de 5 a 7 miembros;Cada R2 es independientemente seleccionado de hidrógeno, alquilo (C1-C6)-recto o ramificado, o alquenilo o alquinilo (C2-C6)-recto o ramificado;X se selecciona de C(R2)2, N(R2), N, O, S, S(O), o S(O)2;Y se selecciona de un enlace, -O-, alquilo (C1-C6)-recto o ramificado, o alquenilo o alquinilo (C2-C6)-recto o ramificado; en donde Y está unido al anillo descrito vía un enlace simple o un enlace doble; y en donde uno a dos de los grupos CH2 de dicho alquilo, alquenilo o alquinilo está opcional e independientemente reemplazado con O, As, S(O), S(O)2, C(O) o N(R2);Z es -C(O)- o -CH2-P es 0, 1 o 2;Cada uno de A y B es independientemente seleccionado de hidrógeno o Ar; o uno de A o B está ausente; yEn donde dos átomos del anillo de carbono en la estructura del anillo descrita están opcionalmente unidos uno al otro por vía de un alquilo C1-C4 recto o un alquenilo C2-C4 recto para crear una porción bicíclica.
CO01009891A 2000-02-11 2001-02-09 Derivados de piperazina y piperidina CO5261503A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18194400P 2000-02-11 2000-02-11
US24733000P 2000-11-10 2000-11-10

Publications (1)

Publication Number Publication Date
CO5261503A1 true CO5261503A1 (es) 2003-03-31

Family

ID=26877657

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01009891A CO5261503A1 (es) 2000-02-11 2001-02-09 Derivados de piperazina y piperidina

Country Status (23)

Country Link
EP (1) EP1257544B1 (es)
JP (1) JP2003522767A (es)
KR (1) KR20020073586A (es)
CN (1) CN1210274C (es)
AP (1) AP2002002596A0 (es)
AU (1) AU4146401A (es)
BR (1) BR0108175A (es)
CA (1) CA2398822A1 (es)
CO (1) CO5261503A1 (es)
CZ (1) CZ20022720A3 (es)
EA (1) EA200200847A1 (es)
EE (1) EE200200442A (es)
HR (1) HRP20020737A2 (es)
HU (1) HUP0301391A3 (es)
IL (1) IL150849A0 (es)
IS (1) IS6477A (es)
MX (1) MXPA02007790A (es)
NO (1) NO20023787L (es)
NZ (1) NZ520638A (es)
PE (1) PE20011081A1 (es)
PL (1) PL357177A1 (es)
SK (1) SK11452002A3 (es)
WO (1) WO2001058891A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809093B2 (en) * 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
IL157253A0 (en) * 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA2439149C (en) 2001-02-28 2012-04-24 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002067869A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP4336196B2 (ja) 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
WO2003022835A1 (en) 2001-09-06 2003-03-20 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1441728A2 (en) * 2001-11-01 2004-08-04 Vertex Pharmaceuticals Incorporated Modulators of the cholesterol biosynthetic pathway
AU2003268493A1 (en) 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
ES2324293T3 (es) * 2002-10-03 2009-08-04 Vertex Pharmaceuticals Incorporated Derivados de piperacina y piperidina para el tratamiento de enfermedades neurologicas.
AR043434A1 (es) 2003-03-03 2005-07-27 Merck & Co Inc Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
CA2523426C (en) 2003-04-24 2013-02-26 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
EP1773338B1 (en) 2004-07-19 2010-01-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
ATE450525T1 (de) * 2005-06-20 2009-12-15 Schering Corp Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten
ES2337727T3 (es) 2005-06-20 2010-04-28 Schering Corporation Derivados de piperidina utiles como antagonistas de histamina h3.
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
MX2020011652A (es) * 2013-07-31 2022-09-27 Novartis Ag Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
JP6985179B2 (ja) * 2018-02-27 2021-12-22 田辺三菱製薬株式会社 プロリンアミド化合物の製造方法
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
US3862937A (en) * 1972-02-23 1975-01-28 Univ Mississippi 6-Phenethyl-3-piperidinecarboxamides
FR2597100A1 (fr) * 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
US5232923A (en) * 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
NZ228329A (en) * 1988-03-18 1991-12-23 Mitsui Toatsu Chemicals Catechol derivatives and pharmaceutical compositions thereof
US5290793A (en) * 1989-09-12 1994-03-01 Mitsui Toatsu Chemicals, Incorporated Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same
FR2705095B1 (fr) 1993-05-12 1995-06-23 Adir Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
PA8442401A1 (es) * 1996-12-09 2000-05-24 Guilford Pharm Inc Inhibidores polipropilos de ciclofilina
JPH11106375A (ja) * 1997-08-18 1999-04-20 Pfizer Pharmaceut Inc ブラジキニンアンタゴニストとしての光学的に活性な１，４−ジヒドロピリジン化合物

Also Published As

Publication number Publication date
CN1404477A (zh) 2003-03-19
HRP20020737A2 (en) 2005-10-31
AU4146401A (en) 2001-08-20
WO2001058891A3 (en) 2002-04-25
NO20023787D0 (no) 2002-08-09
AP2002002596A0 (en) 2002-09-30
CA2398822A1 (en) 2001-08-16
NZ520638A (en) 2004-05-28
CN1210274C (zh) 2005-07-13
EE200200442A (et) 2003-12-15
BR0108175A (pt) 2003-01-28
KR20020073586A (ko) 2002-09-27
NO20023787L (no) 2002-10-11
MXPA02007790A (es) 2002-10-17
JP2003522767A (ja) 2003-07-29
HUP0301391A3 (en) 2010-03-29
HUP0301391A2 (hu) 2003-08-28
EA200200847A1 (ru) 2003-02-27
IL150849A0 (en) 2003-02-12
IS6477A (is) 2002-07-19
WO2001058891A2 (en) 2001-08-16
EP1257544A2 (en) 2002-11-20
CZ20022720A3 (cs) 2002-11-13
PL357177A1 (en) 2004-07-26
PE20011081A1 (es) 2001-10-22
SK11452002A3 (sk) 2003-03-04
EP1257544B1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CO5261503A1 (es) Derivados de piperazina y piperidina
CO5080733A1 (es) Metodos y composiciones para estimular el crecimiento de neuritas
NO971862L (no) Nye inhibitorer av metalloprotease, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
CO5080732A1 (es) Compuestos que poseen actividad neuronal
NO20002796L (no) Kombinert fremgangsmåte for forbedret hydrogenbehandling av dieseldrivstoffer
NO996250D0 (no) Nye hydrazidforbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
CO5150230A1 (es) Derivados de azetidina, su preparacion y los medicamentos que los contienen
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
ES2172744T3 (es) Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.
NO20030301L (no) Nye heteroarylderivater og anvendelse derav som farmasöytika
NO20014102L (no) Nye tricykliske forbindelser og deres anvendelse innenfor medisin, fremgangsmåte for deres fremstilling og farmasöytisksammensetning som inneholder dem
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
HUP0402263A3 (en) Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors, process for their preparation and pharmaceutical compositions containing them
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
RU98115589A (ru) Конденсированные пирролкарбоксанилиды; новый класс лигандов мозговых рецепторов гамк
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
JO2283B1 (en) Pyrimidinyl-N-Acyl-L-Phenyl Anines
IL128036A0 (en) Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
CA2417500A1 (en) Erbb-2 selective small molecule kinase inhibitors
NO20020779L (no) Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet
NO20024192L (no) Klatratkomplekser dannet ved hjelp av hyaluronsyrederivater og anvendelse derav som farmasöytiske midler
ES2119094T3 (es) Inhibicion de la hemorragia uterina disfuncional.
Ahmad Ganai Novel approaches towards designing of isoform-selective inhibitors against class II histone deacetylases: the acute requirement for targetted anticancer therapy
NO20032371L (no) Makrolidsolvater